2022-502831-20-00
Recruiting
Phase 1
A Phase I trial to establish the safety and maximum tolerated dose of high-affinity autologous BCMA-targeting CAR-T cells in patients with relapsed and refractory B-cell malignancies (CARLOTTA01)
Technische Universitat Dresden1 site in 1 country16 target enrollmentStarted: November 3, 2023Last updated:
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Technische Universitat Dresden
- Enrollment
- 16
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Prof. Dr. Martin Wermke
Scientific
Technische Universitat Dresden
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Phase IB Study to determine efficacy and safety of Durvalumab and/or novel anti-cancer agents, with or without chemotherapy, in patients with previously untreated NSCLC2024-511956-42-00AstraZeneca AB44
Not yet recruiting
Not Applicable
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsNCT07279428Sichuan Baili Pharmaceutical Co., Ltd.33
Completed
Phase 1
A phase Ib study to investigate the safety and effect of BR-0032024-516338-37-00SentryX B.V.6
Not yet recruiting
Phase 1
Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of intravenous single ascending doses of IM-250 in healthy volunteers.2025-523146-27-00Innovative Molecules GmbH30
Not yet recruiting
Not Applicable
Safety and Immunogenicity Study of the DuoChol Oral Cholera Vaccine in Healthy ParticipantsNCT07270796International Vaccine Institute60